Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZB004 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ZB004 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ZB004 | DRUG | ZB004 single doses administered subcutaneously as solution |
| Placebo | DRUG | Placebo single doses administered subcutaneously as solution |
Inclusion Criteria: * Healthy male or female participants 18 to 55 years of age. * Body weight ≥ 50 kg for male participants and ≥ 45 kg for female participants; body mass index of 18 to 35 kg/m\^2 for both male and female participants. * Considered in good health as determined by the Investigator....
ZB004 is an investigational small molecule being developed by Zenas BioPharma, Inc. It has been studied in a Phase 1 clinical trial in healthy volunteers. ZB004 is designed to target IGF1R, a receptor. Its therapeutic indications have not been disclosed, and it remains in clinical development.
ZB004 targets IGF1R, the insulin-like growth factor 1 receptor. IGF1R is a cell surface receptor, and ZB004 is a small molecule directed at it. Targeting this receptor is the mechanism described for the investigational compound as it continues through early clinical development.
ZB004 is being developed by Zenas BioPharma, Inc., which trades under the ticker ZBIO. The company is the sponsor of the clinical program evaluating ZB004. The asset is an investigational small molecule and has not been approved for any indication.
ZB004 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The study was a randomized, double-blind, placebo-controlled trial of 40 healthy participants conducted in New Zealand.
ZB004 has been evaluated in one completed Phase 1 trial, NCT05794516, titled A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants. The trial enrolled 40 healthy volunteers in New Zealand, was randomized, double-blind, and placebo-controlled, and included participants aged 18 years and older.